

# M100

## Performance Standards for Antimicrobial Susceptibility Testing

This document includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02, M07, and M11.

A CLSI supplement for global application.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## **Appeal Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## **Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

---

## Performance Standards for Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD  
Jean B. Patel, PhD, D(ABMM)  
April M. Bobenchik, PhD, D(ABMM)  
Shelley Campeau, PhD, D(ABMM)  
Sharon K. Cullen, BS, RAC  
Marcelo F. Galas  
Howard Gold, MD, FIDSA  
Romney M. Humphries, PhD, D(ABMM)  
Thomas J. Kirn, Jr., MD, PhD

James S. Lewis II, PharmD, FIDSA  
Brandi Limbago, PhD  
Amy J. Mathers, MD, D(ABMM)  
Tony Mazzulli, MD, FACP, FRCP(C)  
Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA  
Michael Satlin, MD, MS  
Audrey N. Schuetz, MD, MPH, D(ABMM)  
Jana M. Swenson, MMSc  
Pranita D. Tamma, MD, MHS

### Abstract

The data in the tables are valid only if the methodologies in CLSI documents M02,<sup>1</sup> M07,<sup>2</sup> and M11<sup>3</sup> are followed. These standards contain information about disk diffusion (M02<sup>1</sup>) and dilution (M07<sup>2</sup> and M11<sup>3</sup>) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02,<sup>1</sup> M07,<sup>2</sup> and M11.<sup>3</sup> Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*. 29th ed. CLSI supplement M100 (ISBN 978-1-68440-032-4 [Print]; ISBN 978-1-68440-033-1 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2019.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).

Copyright ©2019 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

**Suggested Citation\***

CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

**Previous Editions:**

December 1986, December 1987, December 1991, December 1992, December 1994, December 1995, January 1997, January 1998, January 1999, January 2000, January 2001, January 2002, January 2003, January 2004, January 2005, January 2006, January 2007, January 2008, January 2009, January 2010, June 2010, January 2011, January 2012, January 2013, January 2014, January 2015, January 2016, January 2017, January 2018

ISBN 978-1-68440-032-4 (Print)  
ISBN 978-1-68440-033-1 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 39, Number 1

---

\* M100, 29th ed. was re-released in March 2019 with a clinically important revision to daptomycin breakpoints in Table 2D. Please see the full memo on the CLSI website (<https://www.clsi.org/standards-development/document-correction-notice>) for more information.

## Committee Membership

### Subcommittee on Antimicrobial Susceptibility Testing

<b>Melvin P. Weinstein, MD</b> <b>Chairholder</b> <b>Rutgers Robert Wood Johnson Medical School</b> USA	Romney M. Humphries, PhD, D(ABMM) Accelerate Diagnostics, Inc. USA	Tony Mazzulli, MD, FACP, FRCP(C) Mount Sinai Hospital Canada
<b>Jean B. Patel, PhD, D(ABMM)</b> <b>Vice-Chairholder</b> <b>Centers for Disease Control and Prevention</b> USA	Thomas J. Kirm, Jr., MD, PhD Rutgers Robert Wood Johnson Medical School USA	Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA Cleveland Clinic USA
Sharon K. Cullen, BS, RAC Beckman Coulter, Inc. Microbiology Business USA	James S. Lewis II, PharmD, FIDSA Oregon Health and Science University USA	Michael Satlin, MD, MS New York Presbyterian Hospital USA
Marcelo F. Galas Pan American Health Organization USA	Brandi Limbago, PhD Centers for Disease Control and Prevention USA	Audrey N. Schuetz, MD, MPH, D(ABMM) Mayo Clinic USA
Howard Gold, MD, FIDSA Beth Israel Deaconess Medical Center USA	Amy J. Mathers, MD, D(ABMM) University of Virginia Medical Center USA	Pranita D. Tamma, MD, MHS Johns Hopkins University School of Medicine USA

### Acknowledgment

CLSI and the Subcommittee on Antimicrobial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the development of this document:

April M. Bobenchik, PhD, D(ABMM) Lifespan Academic Medical Center USA	Shelley Campeau, PhD, D(ABMM) Accelerate Diagnostics, Inc. USA	Jana M. Swenson, MMSc USA
---	--	------------------------------

### Working Group on AST Breakpoints

<b>George M. Eliopoulos, MD</b> <b>Co-Chairholder</b> <b>Beth Israel Deaconess Medical Center</b> USA	Amy J. Mathers, MD, D(ABMM) University of Virginia Medical Center USA	Simone M. Shurland FDA Center for Devices and Radiological Health USA
<b>James S. Lewis II, PharmD, FIDSA</b> <b>Co-Chairholder</b> <b>Oregon Health and Science University</b> USA	David P. Nicolau, PharmD, FCCP, FIDSA Hartford Hospital USA	Lauri D. Thrupp, MD University of California Irvine Medical Center USA
<b>Karen Bush, PhD</b> <b>Committee Secretary</b> <b>Indiana University</b> USA	Robin Patel, MD Mayo Clinic USA	Hui Wang, MD Peking University People's Hospital China
Marcelo F. Galas Pan American Health Organization USA	Michael Satlin, MD, MS New York Presbyterian Hospital USA	Barbara L. Zimmer, PhD Beckman Coulter, Inc. USA

### **Working Group on Methods Application and Interpretation**

**Thomas J. Kirn, Jr., MD, PhD**  
**Co-Chairholder**  
**Rutgers Robert Wood Johnson Medical School**  
**USA**

**Brandi Limbago, PhD**  
**Co-Chairholder**  
**Centers for Disease Control and Prevention**  
**USA**

**Patricia J. Simner, PhD, D(ABMM)**  
**Committee Secretary**  
**Johns Hopkins Hospital - Pathology**  
**USA**

Darcie E. Carpenter, PhD, CIC  
IHMAUSA  
  
Stephen G. Jenkins, PhD, D(ABMM),  
F(AAM)  
Weill Cornell Medicine  
USA

Kristie Johnson, PhD, D(ABMM)  
University of Maryland, Baltimore  
USA

Joseph Kuti, PharmD  
Hartford Hospital  
USA

Samir Patel, PhD, FCCM, D(ABMM)  
Public Health Ontario  
Canada

Virginia M. Pierce, MD  
Massachusetts General Hospital  
USA

Sandra S. Richter, MD, D(ABMM),  
FCAP, FIDSA  
Cleveland Clinic  
USA

Susan Sharp, PhD, D(ABMM),  
F(AAM)  
Copan Diagnostics, Inc.  
USA

### **Working Group on Methods Development and Standardization**

**Dwight J. Hardy, PhD**  
**Co-Chairholder**  
**University of Rochester Medical Center**  
**USA**

**Barbara L. Zimmer, PhD**  
**Co-Chairholder**  
**Beckman Coulter, Inc.**  
**USA**

**Katherine Sei, BS**  
**Committee Secretary**  
**Beckman Coulter, Inc.**  
**USA**

William B. Brasso, BS  
BD Diagnostic Systems  
USA

Susan Butler-Wu, PhD, D(ABMM),  
SM(ASCP)  
LACUSC Medical Center  
USA

Jennifer Dien Bard, PhD, D(ABMM),  
F(CCM)  
Children's Hospital Los Angeles;  
University of Southern California  
USA

Tanis Dingle, PhD, D(ABMM), FCCM  
Provincial Laboratory for Public Health  
Canada

Romney M. Humphries, PhD,  
D(ABMM)  
Accelerate Diagnostics, Inc.  
USA

Laura M. Koeth, MT(ASCP)  
Laboratory Specialists, Inc.  
USA

Ribhi M. Shawar, PhD, D(ABMM)  
FDA Center for Devices and  
Radiological Health  
USA

## Working Group on Outreach

**Janet A. Hindler, MCLS, MT(ASCP)**  
**Co-Chairholder**  
 USA

April M. Bobenchik, PhD, D(ABMM)  
 Lifespan Academic Medical Center  
 USA

Nicole Scangarella-Oman, MS, BS,  
 GlaxoSmithKline  
 USA

**Audrey N. Schuetz, MD, MPH,**  
**D(ABMM)**  
**Co-Chairholder**  
 Mayo Clinic  
 USA

Angella Charnot-Katsikas, MD  
 The University of Chicago  
 USA

Paula M. Snippes Vagnone,  
 MT(ASCP)  
 Minnesota Department of Health  
 USA

**Stella Antonara, PhD, D(ABMM)**  
**Committee Secretary**  
 OhioHealth  
 USA

Graeme Forrest, MBBS  
 Oregon Health Sciences University  
 USA

Lars F. Westblade, PhD, D(ABMM)  
 New York Presbyterian Hospital -  
 Weill Cornell Campus  
 USA

April Abbott, PhD  
 Deaconess Hospital Laboratory  
 USA

Romney M. Humphries, PhD,  
 D(ABMM)  
 Accelerate Diagnostics, Inc.  
 USA

## Working Group on Quality Control

**Sharon K. Cullen, BS, RAC**  
**Co-Chairholder**  
 Beckman Coulter, Inc. Microbiology  
 Business  
 USA

Dana C. Dressel, MT(ASCP)  
 International Health Management  
 Associates, Inc.  
 USA

Susan D. Munro, MT(ASCP), CLS  
 USA

**Maria M. Traczewski, BS, MT(ASCP)**  
**Co-Chairholder**  
 The Clinical Microbiology Institute  
 USA

Janet A. Hindler, MCLS, MT(ASCP)  
 USA

David Paisey, BSc  
 Thermo Fisher Scientific  
 United Kingdom

**Michael D. Huband, BS**  
**Committee Secretary**  
 JMI Laboratories  
 USA

Denise Holliday, MT(ASCP)  
 BD Diagnostic Systems  
 USA

Elizabeth Palavecino, MD  
 Wake Forest Baptist Medical Center  
 USA

Erika Matuschek, PhD  
 ESCMID  
 Sweden

Chris Pillar, PhD  
 Micromyx, LLC  
 USA

Patricia S. Conville, MS, MT(ASCP)  
 FDA Center for Devices and  
 Radiological Health  
 USA

Mary K. York, PhD, D(ABMM)  
 MKY Microbiology Consulting  
 USA

## Working Group on Text and Tables

**April M. Bobenchik, PhD, D(ABMM)**  
**Co-Chairholder**  
**Lifespan Academic Medical Center**  
**USA**

Janet A. Hindler, MCLS, MT(ASCP)  
 USA

Dale A. Schwab, PhD,  
 D(ABMM)CM  
 Quest Diagnostics Infectious Disease  
 USA

**Shelley Campeau, PhD, D(ABMM)**  
**Co-Chairholder**  
**Accelerate Diagnostics, Inc.**  
**USA**

Melissa Jones, MT(ASCP), CLS  
 UNC Healthcare  
 USA

Jana M. Swenson, MMSc  
 USA

**Carey-Ann Burnham, PhD, D(ABMM)**  
**Committee Secretary**  
**Washington University School of**  
**Medicine**  
**USA**

Peggy Kohner, BS, MT(ASCP)  
 Mayo Clinic  
 USA

Richard B. Thomson, Jr., PhD,  
 D(ABMM), FAAM  
 Evanston Hospital, NorthShore  
 University HealthSystem  
 USA

Victoria Emma Anikst, BA, CMS,  
 M(ASCP)<sup>CM</sup>  
 UCLA Health  
 USA

Dyan Luper, BS, MT(ASCP)SM, MB  
 BD Diagnostic Systems  
 USA

Maria M. Traczewski, BS,  
 MT(ASCP)  
 The Clinical Microbiology Institute  
 USA

Andrea L. Ferrell, MLS<sup>CM</sup>(ASCP)  
 Becton Dickinson  
 USA

Susan D. Munro, MT(ASCP), CLS  
 USA

Nancy E. Watz, MS, MT(ASCP),  
 CLS  
 Stanford Health Care  
 USA

L. Barth Reller, MD  
 Duke University School of Medicine  
 USA

Flavia Rossi, MD, PhD  
 University of São Paulo  
 Brazil

Mary K. York, PhD, D(ABMM)  
 MKY Microbiology Consulting  
 USA

## Acknowledgment

CLSI and the Subcommittee on Antimicrobial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to their respective working groups and the development of this document:

Darcie E. Carpenter, PhD, CIC  
 IHMA  
 USA

Matthew A. Wikler, MD, FIDSA, MBA  
 IDTD Consulting  
 USA

Mariana Castanheira, PhD  
 JMI Laboratories  
 USA

Barbara L. Zimmer, PhD  
 Beckman Coulter, Inc.  
 USA

## Staff

Clinical and Laboratory Standards Institute  
 USA

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Kristy L. Leirer, MS  
*Editor*

Marcy L. Hackenbrack, MCM, M(ASCP)  
*Project Manager*

Catherine E.M. Jenkins  
*Editor*

Laura Martin  
*Editor*

This page is intentionally left blank.

**Contents**

Abstract.....	i
Committee Membership.....	iii
Overview of Changes.....	xiv
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges .....	xxvii
CLSI Reference Methods vs Commercial Methods and CLSI vs US Food and Drug Administration Breakpoints .....	xxviii
CLSI Breakpoint Additions/Revisions Since 2010.....	xxix
CLSI Epidemiological Cutoff Value Additions/Revisions Since 2015 .....	xxxii
CLSI Archived Resources.....	xxxii
Subcommittee on Antimicrobial Susceptibility Testing Mission Statement .....	xxxiii
Instructions for Use of Tables.....	1
References.....	16
Table 1A. Suggested Groupings of Antimicrobial Agents Approved by the US Food and Drug Administration for Clinical Use That Should Be Considered for Testing and Reporting on Nonfastidious Organisms by Microbiology Laboratories in the United States.....	18
Table 1B. Suggested Groupings of Antimicrobial Agents Approved by the US Food and Drug Administration for Clinical Use That Should Be Considered for Testing and Reporting on Fastidious Organisms by Microbiology Laboratories in the United States.....	24
Table 1C. Suggested Groupings of Antimicrobial Agents Approved by the US Food and Drug Administration for Clinical Use That Should Be Considered for Testing and Reporting on Anaerobic Organisms by Microbiology Laboratories in the United States .....	30
Table 2A. Zone Diameter and MIC Breakpoints for <i>Enterobacteriaceae</i> .....	32
Table 2B-1. Zone Diameter and MIC Breakpoints for <i>Pseudomonas aeruginosa</i> .....	42

**Contents (Continued)**

Table 2B-2. Zone Diameter and MIC Breakpoints for *Acinetobacter* spp. .... 46

Table 2B-3. Zone Diameter and MIC Breakpoints for *Burkholderia cepacia* complex..... 50

Table 2B-4. Zone Diameter and MIC Breakpoints for *Stenotrophomonas maltophilia* ..... 52

Table 2B-5. MIC Breakpoints for Other Non-*Enterobacteriaceae* (Refer to General Comment 1) ..... 54

Table 2C. Zone Diameter and MIC Breakpoints for *Staphylococcus* spp. .... 58

Table 2D. Zone Diameter and MIC Breakpoints for *Enterococcus* spp. .... 68

Table 2E. Zone Diameter and MIC Breakpoints for *Haemophilus influenzae* and *Haemophilus parainfluenzae* ..... 74

Table 2F. Zone Diameter and MIC Breakpoints for *Neisseria gonorrhoeae* ..... 78

Table 2G. Zone Diameter and MIC Breakpoints for *Streptococcus pneumoniae* ..... 82

Table 2H-1. Zone Diameter and MIC Breakpoints for *Streptococcus* spp.  $\beta$ -Hemolytic Group..... 88

Table 2H-2. Zone Diameter and MIC Breakpoints for *Streptococcus* spp. Viridans Group ..... 92

Table 2I. Zone Diameter and MIC Breakpoints for *Neisseria meningitidis* ..... 96

Table 2J. MIC Breakpoints for Anaerobes ..... 100

Table 3A. Tests for Extended-Spectrum  $\beta$ -Lactamases in *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Escherichia coli*, and *Proteus mirabilis* ... 104

Introduction to Tables 3B and 3C. Tests for Carbapenemases in *Enterobacteriaceae* and *Pseudomonas aeruginosa*..... 108

Table 3B. CarbaNP Test for Suspected Carbapenemase Production in *Enterobacteriaceae* and *Pseudomonas aeruginosa* ..... 110

Table 3B-1. Modifications of Table 3B When Using MIC Breakpoints for Carbapenems Described in M100-S20 (January 2010)..... 114

**Contents (Continued)**

Table 3C. Modified Carbapenem Inactivation Methods for Suspected Carbapenemase Production in <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> .....	118
Table 3C-1. Modifications of Table 3C When Using MIC Breakpoints for Carbapenems Described in M100-S20 (January 2010).....	130
Table 3D. Test for Detection of $\beta$ -Lactamase Production in <i>Staphylococcus</i> spp.....	132
Table 3E. Test for Detecting Methicillin (Oxacillin) Resistance in <i>Staphylococcus</i> spp. ....	136
Table 3F. Vancomycin Agar Screen for <i>Staphylococcus aureus</i> and <i>Enterococcus</i> spp.....	140
Table 3G. Test for Detecting Inducible Clindamycin Resistance in <i>Staphylococcus</i> spp., <i>Streptococcus pneumoniae</i> , and <i>Streptococcus</i> spp. $\beta$ -Hemolytic Group .....	142
Table 3H. Test for Detecting High-Level Mupirocin Resistance in <i>Staphylococcus aureus</i> .....	146
Table 3I. Test for Detecting High-Level Aminoglycoside Resistance in <i>Enterococcus</i> spp. (Includes Disk Diffusion).....	148
Table 4A-1. Disk Diffusion QC Ranges for Nonfastidious Organisms and Antimicrobial Agents Excluding $\beta$ -Lactam Combination Agents.....	150
Table 4A-2. Disk Diffusion QC Ranges for Nonfastidious Organisms and $\beta$ -Lactam Combination Agents.....	154
Table 4B. Disk Diffusion QC Ranges for Fastidious Organisms .....	158
Table 4C. Disk Diffusion Reference Guide to QC Frequency.....	162
Table 4D. Disk Diffusion Troubleshooting Guide.....	164
Table 5A-1. MIC QC Ranges for Nonfastidious Organisms and Antimicrobial Agents Excluding $\beta$ -Lactam Combination Agents.....	168
Table 5A-2. MIC QC Ranges for Nonfastidious Organisms and $\beta$ -Lactam Combination Agents.....	174
Table 5B. MIC QC Ranges for Fastidious Organisms (Broth Dilution Methods).....	178
Table 5C. MIC QC Ranges for <i>Neisseria gonorrhoeae</i> (Agar Dilution Method) .....	182

**Contents (Continued)**

Table 5D. MIC QC Ranges for Anaerobes (Agar Dilution Method)..... 184

Table 5E. MIC QC Ranges for Anaerobes (Broth Microdilution Method)..... 186

Table 5F. MIC Reference Guide to QC Frequency ..... 188

Table 5G. MIC Troubleshooting Guide..... 190

Table 6A. Solvents and Diluents for Preparing Stock Solutions of Antimicrobial Agents ..... 194

Table 6B. Preparing Stock Solutions for Antimicrobial Agents Provided With Activity Expressed as Units ..... 200

Table 6C. Preparing Solutions and Media Containing Combinations of Antimicrobial Agents ..... 202

Table 7. Preparing Dilutions of Antimicrobial Agents to Be Used in Agar Dilution Susceptibility Tests..... 206

Table 8A. Preparing Dilutions of Antimicrobial Agents to Be Used in Broth Dilution Susceptibility Tests..... 208

Table 8B. Preparing Dilutions of Water-Insoluble Antimicrobial Agents to Be Used in Broth Dilution Susceptibility Tests ..... 210

Appendix A. Suggestions for Confirming Resistant, Intermediate, or Nonsusceptible Antimicrobial Susceptibility Test Results and Organism Identification ..... 212

Appendix B. Intrinsic Resistance..... 218

Appendix C. QC Strains for Antimicrobial Susceptibility Tests ..... 226

Appendix D. Cumulative Antimicrobial Susceptibility Report for Anaerobic Organisms..... 232

Appendix E. Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Breakpoints ..... 238

Appendix F. Susceptible-Dose Dependent Interpretive Category ..... 242

Appendix G. Epidemiological Cutoff Values ..... 246

**Contents (Continued)**

Appendix H. Using Molecular Assays for Resistance Detection .....	252
Glossary I (Part 1). $\beta$ -Lactams: Class and Subclass Designations and Generic Name.....	266
Glossary I (Part 2). Non- $\beta$ -Lactams: Class and Subclass Designations and Generic Name.....	268
Glossary II. Antimicrobial Agent Abbreviation(s), Route(s) of Administration, and Drug Class.....	272
Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in US Diagnostic Products.....	278
The Quality Management System Approach .....	280
Related CLSI Reference Materials .....	281